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Abstract
Background: Emerging evidence has demonstrated that Neutrophil gelatinase-associated lipocalin
(NGAL) is up-regulated in multiple malignancies, including oesophagus cancer, and plays a critical
role in tumorigenesis and progression. However, till now, little is known about the role of NGAL
in human rectal cancer. Its association with clinicopathologic characteristics and expression of
MMP-9, one of its target genes, has not been reported systematically in rectal cancer. Therefore,
to further determine the potential involvement of NGAL in rectal cancer, we have evaluated the
expression level of NGAL mRNA by real time RT-PCR, and further elucidated the correlation of
NGAL mRNA expression with clinicopathologic features and MMP-9 in rectal cancer.
Methods:  100 paired samples of rectal cancer and adjacent normal tissues obtained from
inpatients undergoing surgical operation were allocated into two groups (cancer group and control
group). The mRNA expression of NGAL and MMP-9 was determined by real-time RT-PCR. The
association between their expression and clinicopathological characteristics of rectal cancer were
analysised.
Results: Among the 100 rectal cancers, 69 cases of NGAL mRNA up-regulation were observed.
NGAL mRNA up-regulation was positively correlated with MMP-9 (rs = 0.393, p < 0.001). In rectal
cancer, NGAL mRNA overexpression was significantly associated with depth of invasion (p =
0.028), lymph node metastasis (p = 0.009), venous involvement (p = 0.023) and advanced pTNM
stage (p = 0.011).
Conclusion: In human rectal cancer, NGAL mRNA expression was elevated. NGAL mRNA up-
regulation was correlated significantly with tumor progression and MMP-9 mRNA overexpression
in rectal cancer, suggesting a more aggressive phenotype. NGAL could be used for rectal cancer
characterization.
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Background
Colorectal cancer (CRC) is one of the common gastroin-
testinal cancers worldwide and the second leading cause
of cancer-related deaths in Europe[1]. In the United
States, colorectal cancer was the third most common
cause of cancer related death in 2007[2]. About 30% to
60% of patients with colorectal cancer undergoing pri-
mary surgery with curative intention still die from meta-
static disease[3]. Compared to colon cancer, rectal cancer,
with worse prognosis, is mainly attributed to higher
advanced cancer resulting from progression and metasta-
sis of the tumor, which are two of the most important fac-
tors in determining the prognosis of patients with rectal
cancers[4]. The early diagnosis of rectal cancer is difficult
owing to the late presentation of symptom. The scarcity of
early biomarkers has considerably hindered our ability to
launch preventive measures for this malignancy in a
timely manner. So it is important to find superior tumor
markers implicated in the progression and metastasis of
human rectal cancer.
NGAL, a 24-kDa glycoprotein, also known as lipocalin-2,
belongs to the lipocalin protein family. The rat NGAL
homologue, neu-related lipocalin (NRL), was first identi-
fied as a gene whose expression was specifically induced
in HER-2/neu oncogene-induced rat mammary carcino-
mas[5]. NGAL exists as monomer (25 kDa), homodimer
(46 kDa), and disulfide-linked heterodimer with Matrix
Metalloproteinase-9 (MMP-9,135 kDa)[6,7]. As a mem-
ber of the MMP family, MMP-9 has been implicated to
cancer progression by degradation of the molecular com-
ponents of the basement membrane and extracellular
matrix, liberating vascular endothelial cell growth factor
(VEGF) from the extracellular matrix and therefore ena-
bling angiogenesis, invasion and distant metastasis [8-
10].
Growing evidence has demonstrated that NGAL can form
a complex with MMP-9 and improves MMP-9 expression,
prevents its degradation, causing increased MMP-9 enzy-
matic activity, thereby favoring invasive and metastatic
potential of cancer cells in vivo and in vitro [11-13].
Elevated NGAL expression has also been detected in a
variety of malignancies and involved in the invasion and
progression of tumors, including breast cancer, esopha-
geal carcinoma and gastric cancer et al [13-15].
Up to now, however, little is known about the role of
NGAL in human rectal cancer. Its association with clinico-
pathologic characteristics and expression of MMP-9, one
of its target genes, in rectal cancer has not been reported
systematically. Therefore, to further determine the poten-
tial involvement of NGAL in rectal cancer, we detected
mRNA expression of NGAL and MMP-9 in matched rectal
samples by real time RT-PCR, and further evaluated the
correlation between NGAL and MMP-9 as well as clinico-
pathological features in human rectal cancer.
Methods
Patients and specimens
100 paired samples of rectal cancer and adjacent normal
tissues were obtained from inpatients undergoing surgical
operation from January 2006 to September 2008 at the
Department of Oncological Surgery, the First Affiliated
Hospital of Wenzhou Medical College. These inpatients
did not receive any chemotherapy and radiotherapy
before operation. This study was approved by the institu-
tional review board and all patients provided written
informed consent to participate. The rectal cancer and
paired normal rectal tissues were allocated to a cancer and
a control group respectively. The adjacent normal tissues
were distant from the corresponding rectal cancer tissues
more than 5 cm. The samples of rectal cancer and adjacent
normal tissues were away from the region of obvious
inflammation and necrosis. The immunohistochemistry
Staining was routinely performed by the Department of
Pathology of the First Affiliated Hospital of Wenzhou
Medical College in order to exclude the cases with obvious
inflammation and necrosis response, and to reduce the
potential interference by neutrophils. All dissected speci-
mens were cut into 5-mm cubic blocks, snap frozen in liq-
uid nitrogen immediately and stored at -80°C. Tumor
grade of differentiation was defined according to the
WHO criteria[16]. The clinical and pathological stages
were defined according to pTNM stage. The histopatho-
logical examination was conducted by the Department of
Pathology of the First Affiliated Hospital of Wenzhou
Medical College. As shown in table 1, specific primers and
probes for NGAL gene, MMP-9 gene and glyceraldehydes-
3 phosphate (GAPDH) gene (reference gene) were
designed based on sequence data from the Ensembl data-
base http://www.ensembl.org. Primers and probe were
placed at the junction between 2 exons. All primers and
probes were synthesized by Takara Biotechnology Co., Ltd
(Dalian, China).
Real-time RT-PCR
Real-time RT-PCR was performed using a relative quanti-
fication protocol on an iCycler iQ System (Bio-Rad, Her-
cules, Calif., USA). The optimal conditions for the
amplification of NGAL consisted of 2 min at 94°C fol-
lowed by 40 cycles for 30 s at 94°C, 30 s at 51°C and 30
s at 71°C. The optimal conditions for the amplification of
MMP-9 consisted of 2 min at 94°C followed by 40 cycles
for 30 s at 94°C, 30 s at 56°C and 30 s at 71°C. In addi-
tion, a no-template control (double-distilled H2O con-
trol) was included for each master mix. All samples wereBMC Cancer 2009, 9:134 http://www.biomedcentral.com/1471-2407/9/134
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amplified simultaneously in triplicate in a one-assay run.
The amplified products were resolved by electrophoresis
in 2.0% agarose gel and visualized by ethidium bromide
staining. GAPDH was performed simultaneously as a
standard internal control. The relative expression ratio (R)
and real-time RT-PCR efficiency (E) of samples were deter-
mined by the following equations, as described in previ-
ous study[17,18].
[17]
[18]
The CT value is the cycle number at which the fluores-
cence signal crosses the threshold, and ΔCT is the CT devi-
ation of the control minus the sample of the target or
reference gene transcript. A ratio > 1 represented NGAL or
MMP-9 mRNA up-regulation in rectal cancer relative to
the control.
Statistical analysis
SPSS 13.0 software for Windows (SPSS Inc, USA) was used
for statistical analysis. The relative expression analysis and
group-wise comparison of the target gene was performed
by the Relative Expression Software Tool (REST, available
at http://www.gene-quantification.com)[19]. Continuous
variables were expressed as (  ± s). The expression of
NGAL mRNA was assessed for associations with clinico-
pathological characteristics using Student's t-test for age
and the χ2 test for the remaining parameters. Finally, the
correlation between NGAL and MMP-9 was evaluated by
calculating Spearman's correlation coefficient. p  < 0.05
was considered statistically significant.
Results
NGAL and MMP-9 mRNA Expression in Rectal Cancer and 
Paired Normal Rectal Tissues
The mRNA expression of NGAL and MMP-9 was exam-
ined in 100 rectal cancers and paired normal rectal tissues.
Real-time RT-PCR amplification efficiencies were calcu-
lated from the given slopes in the FTC-2000 software
(Fengling Co., Shanghai, China) and REST, and the
amplification efficiency in the 2 groups was 2. As
described above, the relative ratio, R, is presented as the n-
fold change in gene expression normalized to an endog-
enous reference gene and relative to the control. There-
fore, a value of R > 1.0 was considered to represent over
expression of NGAL and MMP-9 gene in the sample rela-
tive to the control.
Among the 100 rectal cancer RNA samples tested, NGAL
and MMP-9 over expression were shown in 69 and 63
cases respectively. Over expression of mRNA NGAL and
MMP-9 was observed as follows: 52 cases both over
expressed, 20 cases both not over expressed, 17 cases
NGAL over expressed but MMP-9 not overexpressed,11
cases MMP-9 over expressed but NGAL not over
expressed. The numeric results of the randomization test
were put in the randomization box. REST analysis showed
mRNA up-regulation of NGAL and MMP-9 in the sample
group was remarkably different from that in the control
group (p = 0.001), that is, it was up regulated in compari-
son to the control group (table 2, Figure 1).
Relationship between NGAL mRNA up-regulation and 
Clinicopathological Features in Rectal Cancer
The relationship between NGAL mRNA up-regulation and
clinicopathological characteristics was analyzed. NGAL
mRNA up-regulation correlated significantly with depth
of invasion (p  = 0.028), lymph node metastasis (p  =
0.009), venous involvement (p = 0.023) and advanced
pTNM stage (p  = 0.011). There was no correlation of
R
Etarget
CTtarget
control sample
Ereference
CTreferen
=
−
()
()
()
Δ
Δ c ce
control sample () −
E
slope =
− 10
1/
x
Table 1: Primers and probes
Sequence
NGAL
Forward primer 5'-ATGACATGAACCTGCTCGATA-3'
Reverse primer 5'-TCATAGTCGTTCATTATCTTC-3'
Probe 5'-FAM- CCTGAAAAGAGTCTCTGCCCA-TAMRA-3'
MMP-9
Forward primer 5'-CTGAAATGACGTCCCTAAGT-3'
Reverse primer 5'-AGGAGGTCTCACTATCTGGAT-3'
Probe 5'-FAM- TCTGACATGCCTCGAGGACCT-TAMRA-3'
GAPDH
Forward primer 5'-CCTCAAGATCATCAGCAAT-3'
Reverse primer 5'-CCATCCACAGTCTTCTGGGT-3'
Probe 5'-FAM- ACCACAGTCCATGCCATCAC-TAMRA-3'BMC Cancer 2009, 9:134 http://www.biomedcentral.com/1471-2407/9/134
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NGAL mRNA with age, gender and grade (p > 0.05, table
3).
Correlation between mRNA up-regulation of NGAL and 
MMP-9 in Rectal Cancer
In rectal cancers, the correlation coefficient between
mRNA up-regulation of NGAL and MMP-9 was 0.393.
NGAL mRNA up-regulation was positively correlated with
MMP-9 (p < 0.001, table 4).
Discussion
This is the first study to apply the real-time RT-PCR
method to quantify the NGAL mRNA expression and to
elucidate the correlation of NGAL mRNA expression with
clinicopathologic features and MMP-9 in human rectal
cancer. The present study observed that 69 cases (69%)
among the 100 rectal cancers showed NGAL mRNA over-
expression, a significantly elevated level of NGAL mRNA
expression with real-time RT-PCR in rectal cancers com-
pared with adjacent normal tissues, which is in agreement
with the report of Nielsen et al. [20] Hypomethylation of
the NGAL gene has been found both in pancreatic and
mammary tumor cell lines, which may be responsible for
its high expression levels [21]. Moreover, we demon-
strated that NGAL mRNA up-regulation correlated signifi-
cantly with MMP-9 and some important
clinicopathological characteristics such as depth of inva-
sion, lymph node metastasis, venous involvement and
advanced pTNM stage (p < 0.05). Depth of invasion,
lymph node metastasis and pTNM stage of rectal cancer
have powerful predictive value to prognosis. Venous inva-
sion by tumor has also been demonstrated to be a stage-
independent adverse prognostic factor [22,23]. This sug-
gests that NGAL not only involved in the progression of
rectal cancer, but also could be a prognostic marker in rec-
tal cancer.
Interestingly, unlike our results, Lee and colleagues[24]
reported that overexpression of NGAL suppressed human
colon cancer KM12SM cell to invade Matrigel in vitro, and
liver metastasis of colon cancer cells injected directly into
the spleens in an mice experimental animal model. These
Table 2: Output of randomisation analysis in 2 groups by REST
GAPDH NGAL MMP-9
Number 100 100 100
PCR efficiencies 22 2
Control means 19.974 29.776 28.555
Sample means 20.077 27.364 26.889
Expression ratios 5.716 3.408
p values 0.001 0.001
Expression ratios-nn 0.931 5.322 3.173
p values-nn 0.709 0.001 0.001
Randomisations 1,000 of 1,000 done
REST: Relative expression software tool.
Sample means: Mean CT values for the rectal cancer tissues.
Control means: Mean CT values for the adjacent normal tissues.
Expression ratios-nn: Expression ratios not normalised.
p values-nn: p values not normalised.
Randomisations: REST (Relative Expression Software Tool) is a 
standalone software tool to estimate up and down regulation for gene 
expression study in real-time PCR by using statistical randomization 
tests, while taking into account issues of reaction efficiency and 
reference gene normalisation. The randomization scenario is as 
follows: "if any perceived variation between samples and controls is 
due only to chance, then we could randomly swap values between the 
2 groups and not see any greater difference than what we see 
between the initial groups."In our study, the hypothesis test performs 
1,000 random reallocations of samples and controls between the 
groups, and counts the number of times the relative expression on 
the randomly assigned group is greater than the sample data.
Output of randomisation analysis in 2 groups by REST Figure 1
Output of randomisation analysis in 2 groups by REST. REST:Relative expression software tool. Genes ref.: GAPDH; 
Genes 1: NGAL; Genes 2: MMP-9 Sample means: Mean CT values for the rectal cancer tissues. Control means:Mean CT values 
for the adjacent normal tissues. Expression ratios-nn: Expression ratios not normalised. p values-nn: p values not normalised.BMC Cancer 2009, 9:134 http://www.biomedcentral.com/1471-2407/9/134
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apparently diverse observations could be due to distinct
functions of NGAL in different cell types, which is further
supported by a previous study demonstrating that NGAL
overexpression could suppress Ras-transformed murine
breast cancer 4T1 cell invasion and lung metastasis in vivo
[25]. However, ectopic expression of NGAL may signifi-
cantly stimulates the growth of MCF-7 human breast can-
cer cells in vivo[12]. Furthermore, such an experimental
metastasis study may also have limitations in reflecting
the whole process of metastasis since the effects on pri-
mary malignancy growth before metastasis could not be
determined. Therefore, future evaluation of NGAL with a
spontaneous metastasis assay was essential so as to eluci-
date the context-specific regulation mechanism.
MMPs are believed to play a crucial role in colorectal can-
cer tumor growth and angiogenesis, thereby promoting
invasion and metastasis. MMP-9 appears to be one of the
most important since it is overexpressed in the majority of
colorectal cancers [26,27]. Several lines of evidence in
vitro or in vivo have suggested that NGAL plays an impor-
tant role in the enhanced invasive potential of cancer cells
by upregulating MMP-9 expression. Yan et al demon-
strated that NGAL is capable of protecting MMP-9 from
degradation in a dose-dependent manner and thereby
preserving MMP-9 enzymatic activity in vitro system by
employing recombinant human MMP-9 and NGAL, as
well as in a cell culture system in which NGAL was over-
expressed in MDA-MB-231 human breast carcinoma cells.
[11]Transfection of an NGAL expression plasmid con-
ferred the invasive phenotype and motility activities of a
noninvasive human breast cancer cell line (MCF-7)
accompanying an increase in MMP-9 expression[12]. Fur-
thermore, down-regulation of NGAL expression in
oesophageal squamous cell carcinoma (ESCC) cells could
significantly suppress MMP-9 activity and the invasion of
these cells in nude mice[28]. Recently, Frank et al have
reported the clinical evidence for a protective role of
NGAL against MMP-9 autodegradation in gastric can-
cer[13]. In present study, we also revealed a significant ele-
vated expression of NGAL and MMP-9 mRNA levels in
human rectal cancer and they all correlated well with
tumor invasion and metastasis. Additionally, NGAL
mRNA overexpression was positively correlated with
MMP-9 mRNA up-regulation (rs = 0.393, p < 0.001). This
suggests that the NGAL-MMP-9 axis could be a potent
therapeutic target in rectal cancer patients. Therapeutic
agents that inhibit the expression or function of NGAL or
of its target genes may prove efficacious, or might comple-
ment agents that directly compromise the MMP-9 activi-
ties in the treatment of human rectal cancer. Studies are
needed to further explore the mechanisms involved.
The spread of malignant tumor cells from a primary
tumor to form metastases at distant sites is the most life-
threatening complication of cancer and is responsible for
the majority of deaths in affected individuals. When
detected at early stages, the majority of CRC can be cured
with high success rates, and there is a strong correlation
between tumor progression at the moment of the diagno-
sis and survival rate[29]. Hence, a marker to identify early
stage cancer would be immensely useful to improve sur-
vival. For this purpose, a number of screening tests have
been developed. However the ideal screening test must be
specific, sensitive and non-invasive. NGAL as a valuable
biomarker for early diagnosis and monitoring relapse of
malignancy has been increasing used. Fernandez et al
Table 3: Relationship between expression of NGAL mRNA and 
clinicopathological characteristics in rectal cancer
Variables/categories NGAL expression P value
ratio ≤ 1r a t i o  >  1
Age, years 63.38 ± 11.1 60.78 ± 13.1 NS
Gender NS
Male 13 31
Female 18 38
Grade NS
Well-differentiated 4 3
Moderately differentiated 20 51
Poorly differentiated 7 15
Depth of invasion 0.028
pT1 5 2
pT2 13 23
pT3 12 33
pT4 1 11
Lymph node metastasis 0.009
Absent 17 19
Present 14 50
Venous involvement 0.023
Absent 26 42
Present 5 27
pTNM stage 0.011
pI 4 2
pII 13 14
pIII 13 44
pIV 1 9
ratio ≤ 1: The expression of NGAL mRNA was not up-regulated; 
ratio > 1: The expression of NGAL mRNA was up-regulated; NS:Not 
significant.
Table 4: Correlation between mRNA up-regulation of NGAL 
and MMP-9
MMP-9 expression NGAL expression Pr
ratio ≤ 1r a t i o  >  1
ratio ≤ 1 20 17 < 0.001 0.393
ratio > 1 11 52
ratio ≤ 1: The expression of NGAL or MMP-9 mRNA was not up-
regulated; ratio > 1: The expression of NGAL or MMP-9 mRNA was 
up-regulated; r: Correlation coefficient.BMC Cancer 2009, 9:134 http://www.biomedcentral.com/1471-2407/9/134
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have demonstrated that NGAL and MMP-9 complexes
were identified in nearly 86.36% of urine sample from
breast cancer patients whereas this molecule is undetecta-
ble in the urine of healthy controls, suggesting that uri-
nary NGAL may represent a novel, non-invasive
biomarker for tracking disease status and the effectiveness
of anticancer therapy in NGAL positive breast carcino-
mas[12]. In addition, serum NGAL measurement by
ELISA is fairly accurate in distinguishing pancreatic cancer
from non-cancer cases and could be investigated as a
marker of pancreatic intraepithelial neoplasia (PIN) for
early diagnosis of pancreatic cancer[30]. Furthermore, uri-
nary NGAL and MMP-9 are useful predictors of the pres-
ence of brain tumors and may provide a basis for a novel,
non-invasive method to identify new brain tumors and
monitor known tumors after treatment[31]. Recently, Lim
and colleagues[32] have also demonstrated that NGAL
involved in the progression of epithelial ovarian malig-
nanciesmay and may be served as an early screening
biomarker to monitor changes of benign to premalignant
and malignant ovarian tumors. This raises the possibility
that serum and urine NGAL measurement (or combina-
tion with other potential biomarkers such as MMP-9)
could also be explored as a utility for detecting disease sta-
tus, progression, and therapeutic efficacy through nonin-
vasive surveillance in rectal cancers, which deserves our
attention.
Conclusion
Till now, little is known about the potential involvement
of NGAL in human rectal cancer. In present study, we
detected the mRNA expression of NGAL and MMP-9 in
human rectal cancer by real-time RT-PCR. Our research
demonstrated that NGAL mRNA expression was elevated
in human rectal cancer. NGAL mRNA up-regulation was
correlated significantly with tumor progression and MMP-
9 mRNA overexpression in rectal cancer, suggesting a
more aggressive phenotype. NGAL detection may provide
valuable information for rectal cancer characterization
and identification of a subset of patients requiring more
aggressive adjuvant therapy. As a secreted molecule,
NGAL may serve as an attractive therapeutic target. Fur-
ther studies are needed to elucidate the precise mecha-
nisms of NGAL implicated in cancer progression and its
potential utility in rectal cancer treatment.
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